Objective: The aryloxypropanolamine carvedilol is a multiple action cardiovascular drug with blocking effects on a-receptors,
Introduction
major cause of death. In theory, the prolongation of the cardiac refractory period makes the heart less susceptible In cardiomyocytes, the rapid component of the delayed for cardiac arrhythmias [18] . Although, prolonging the 1 rectifier K current, I [4] is an important repolarizing refractory period has the possibility of both antiarrhythmic Kr 1 potassium current. I is encoded by the human ether-a-goand proarrhythmic potential, particularly where Na chanKr go-related gene (HERG) . This has been demonstrated in nel blockade increases both the refractory period and the macroscopic current measurements [37, 47] and single vulnerable period [43, 44, 9] . For class III antiarrhythmic channel measurements [22, 53] . Many class III antiarrhythdrugs, outcomes of clinical trials show overall beneficial mic drugs prolong the cardiac action potential and thereby effects for amiodarone [5, 35, 13 ] and significant increases the refractory period by blocking I . Likewise, block of of the postinfarction mortality for the pure class III drug Kr HERG channels by various drugs has been investigated D-sotalol [49] . previously [40, 22, 23, 45, 46, 3, 51, 20] .
The aryloxypropanolamine carvedilol (1-(9H-carbazolIn patients after myocardial infarction [19, 36, 10] and 4-yloxy)-3-[[2-(2 -methoxyphenoxy)ethyl]amino]-2-propadilated cardiomyopathy [26, 17, 50] 38] is part of its neurohumoral properties. It is a calcium-channel blocker [32] and sodium-channel modulator [27] . ing began 30 s after solution switch. All measurements It has inhibitory effects on N-methyl-D-aspartate (NMDA) were done under steady-state conditions at least 2 min after receptors [27] and antioxidant activity has also been total solution exchange. described for carvedilol [52] . Microelectrodes had tip resistances ranging from 1 to 5 carvedilol, resulting in a prolongation of cardiac action MV. Data were low-pass filtered at 1-2 kHz (23 dB, potential [6] . However, in ECGs of patients treated with four-pole Bessel filter) before digitalization at 5-10 kHz. carvedilol, a significant QT prolongation was not observed
Recordings were performed using a commercially avail- [39] . tial, Y the degree of steady-state inactivation and k is the slope factor.
Methods
Statistical data are expressed as mean6standard error where n represents the number of experiments performed.
Solutions and drug administration
Statistical significance was evaluated using the paired Student's t-test. Differences were considered to be signifiTwo-microelectrode voltage clamp measurements of cant when the P value was ,0.05. Xenopus oocytes were performed in a physiologically low 1 K solution containing (in mM) 5 KCl, 100 NaCl, 1.5 CaCl , 2 MgCl , and 10 HEPES (pH 7.3). Current and 2.3. Expression of HERG channels in Xenopus oocytes 2 2 voltage electrodes were filled with 3 M KCl solution. Carvedilol (Hoffmann-La Roche, USA) was dissolved in The HERG clone was a gift from M.T. Keating (Salt ethanol to a stock solution of 100 mM and stored at 148C. Lake City, UT, USA). HERG complementary RNA was On the day of experiments, aliquots of the stock solution prepared from the HERG cDNA [37] in the pSP64 plasmid were diluted to the desired concentration with the bath with the mMESSAGE mMACHINE in vitro transcription solution. With the highest concentration of 100 mM of the kit (Ambion) by use of SP6 polymerase after linearization drug, the ethanol concentration was 0.1%; although, 0.1% with EcoRI (Boehringer Mannheim). Injection of RNA ethanol alone only minimally reduced inward tail currents (50-500 ng / ml) into stage V and VI defolliculated oocytes (by 2.0760.89%, n53, at 2120 mV, after a test pulse to was performed by using a Nanoject automatic injector 100 mV; data not shown). All measurements were carried (Drummond, Broomall, USA). The volume of injected out at room temperature (208C). The volume of the bath cRNA solution was 50 nl per oocyte, and measurements chamber was 150 ml; after solution switch, it took about 4 were made 2-10 days after injection. The investigation s for the new solution to reach the bath (tubing length of conforms with the Guide for the Care and Use of about 37 cm); at a flow-rate of 1 ml / min, solution in the Laboratory animals published by the US National Instibath was totally exchanged within 9 s. In general, recordtutes of Health (NIH publication No. 85-23, revised 1996).
Results
potential of 280 mV test pulses from 280 to 180 mV in 10-mV increments (400 ms) were applied at a frequency of K currents, two-microelectrode voltage clamp experiactivation threshold of 240 mV, reached a current maximents were performed on Xenopus oocytes heterologously mum at 10 mV before a considerable current reduction at expressing the HERG channel. First the control measurehigher test pulse amplitudes could be measured, as a result ments were obtained (Fig. 1A) , then the carvedilol (10 of inward rectification. Fig. 1C shows the current-voltage mM) was washed into the bath for 10 min, and the relationship (I-V curve) at the end of the test pulse. After measurements with carvedilol ( Fig. 1B) were made. Curapplication of 10 mM carvedilol (Fig. 1B) , the peak current rents were measured with an I-V protocol. From a holding amplitude (at 10 mV) was reduced by 46.163.6% (n54;
1 Fig. 1 . Inhibition of HERG K currents by carvedilol. Upper graph: Original recordings obtained before (A) and after (B) exposure to 10 mM carvedilol for a typical measurement in a Xenopus oocyte expressing HERG potassium channels. The maximum outward current (after a test pulse to 0 mV) was reduced by 44.1% (C). The peak tail current was reduced by 50.7% after the test pulse to 30 mV (D). Activating currents normalized to their peak are shown in (E) tail currents normalized to their maximum are shown in (F). Pulse protocol: Holding potential 280 mV, test pulses from 280 to 180 mV (400 ms) in 10-mV increments, followed by a return pulse to 260 mV. Fig. 1C ). Under carvedilol, the increase of activating the peak tail current amplitude (after a test pulse to 40 mV) current graph with subsequent saturation developed faster by 46.563.7% (n54) (Fig. 1D ). Normalized activating than in the control, which has to be interpreted as a sign of and normalized tail currents for control and 10 mM open channel block.
carvedilol were scaled in Fig. 1E and F. The amplitude of the outward tail currents in the return pulse partially exceeded the amplitude of the activating 3.2. Onset of block and washout of the carvedilol effect current due to slow activation, fast inactivation, rapid recovery from inactivation and slow deactivation. (This Subsequently, a series of 50 constant pulses to 30 mV has been described elsewhere [22, 24, 37, 40] ). Tail currents (400 ms) at a frequency of 0.07 Hz served to investigate 1 saturated after a test pulse amplitude of 140 mV or above the onset of carvedilol-induced inhibition of HERG K (Fig. 1D ). Carvedilol in a concentration of 10 mM reduced outward tail currents ( Fig. 2A) . After nine recordings, Fig. 2 . Onset of block and washout of the carvedilol effect. At a frequency of 0.07 Hz, a series of fifty current recordings, respectively, served to investigate onset and washout of HERG tail current block by carvedilol (A and B). Corresponding currents normalized to the peak activating current are shown in (C and D). After nine control measurements (0-150 s) demonstrating the stability of the experimental conditions, carvedilol in a concentration of 10 mM was perfused into the bath and achieved an inhibition of 36.2% within 90 s. After 12 min, the inhibition was 47.7% (E). In a subsequent series, carvedilol was washed out after another nine measurements resulting in a partial recovery of current by 60.4% (F (Fig. 2B) . After nine recordings during steady-state block by 10 mM carvedilol, the substance was washed out. The washout was almost complete within 3 min, reaching 80.061.0% (n53) of the current amplitude at the beginning of the experiment (Fig.  2F) . Currents in Fig. 2A and B were normalized to the peak activating current in Fig. 2C and D. During the first 400 ms of activation, a time-dependent decrease of current with 10 mM carvedilol could be registered (Fig. 2C) , a sign for fast open channel block. After washout, this current decrease was reversible (Fig. 2D ).
Concentration-dependence of block
The concentration-dependence of carvedilol-induced 1 inhibition was measured on HERG K tail current amplitudes. From a holding potential of 280 mV, test pulses to 130 mV (400 ms) and return pulses to 260 mV (400 ms) were applied (Fig. 3A) . The effect of carvedilol on the tail current at 260 mV was concentration dependent, i.e. carvedilol in a concentration of 0.1, 1, 10, 100 mM blocked the tail current to 96.061.8, 91.662.2, 53.164.5, 14.467.6% (n54) of the control, respectively. The nor- To measure inactivation, a special protocol was used that inactivates the channel at a holding potential of 120 mV, recovers the channel from inactivation at various test pulse potential, giving the steady-state inactivation potentials from 2120 to 30 mV (15 ms) in 10-mV steps, curve. This curve could be fitted with a Boltzmann and measures the resulting peak outward current at condistribution and did not show any significant shift after the stant 120 mV as a measure of steady-state inactivation application of carvedilol in four experiments [DV 5
1 / 2 (Fig. 4C) . Having obtained the control measurement 2 0.9162.85 mV, P.0.05, (n54 experiments)]. shown in Fig. 4A , we washed in carvedilol at a con-1 centration of 10 mM for 15 min and held the oocyte during 3.5. Carvedilol does not affect activation of HERG K this period of time at 280 mV. In this set of experiments, a currents holding potential of 280 mV was necessary to prevent destruction of the oocyte that usually occurs when holding
The effect of carvedilol on activation kinetics of HERG 1 the oocyte 15 min at 120 mV. Finally, the measurements K currents was investigated by measuring activation with carvedilol were made, as shown in Fig. 4B. In Fig. curves. Activation curves were obtained with a protocol, 4D, the inactivating outward current amplitude (measured where we applied variable test pulses ranging from 2120 at constant 20 mV) was normalized and plotted against the to 1100 mV (200 ms) in 10-mV increments, and measured Activation curves of HERG K currents were measured in a protocol current. To measure inactivation, a special protocol was used that with inward tail currents in a representative experiment. The control inactivates the channel at a holding potential of 120 mV, recovers the measurement is shown in (A). The measurement with carvedilol is shown channel from inactivation at various potentials from 2120 to 30 mV (15 in (B). In (C) the tail current amplitude is displayed against the test pulse ms) in 10-mV steps, and measures the resulting peak outward current at voltage in the previous step. In (D) the inverted tail current amplitude constant 120 mV as a measure of steady-state inactivation. Resulting was displayed as a function of the previous test pulse potential resulting outward currents 2 ms after the final step to 120 mV were displayed for in an activation curve. There was no significant shift in the normalized control (A) and 10 mM carvedilol (B) as a function of the test pulse activation curve from n54 experiments (D). Voltage protocol: Holding potential in (C). Current amplitudes were normalized resulting in the potential 280 mV, test pulses from 280 to 180 mV in 10-mV increments inactivation curves in (D). Carvedilol did not produce any shift in the (200 ms) return pulses constant 2120 mV to measure tail currents. normalized steady-state inactivation curves from n54 experiments.
No frequency and no use-dependence of carvedilol
the corresponding inward tail current amplitude at 2120 block mV ( Fig. 5A and B) . The inverted tail current amplitude was displayed against the test pulse potential, resulting in a After carvedilol block reached steady-state conditions normalized tail current curve that was a measure of steady-(after 2 min) the frequency dependence of block was 1 state activation (Fig. 5C ). In Fig. 5D the activation curves investigated. HERG K channels were activated by defor control and with carvedilol (10 mM) were normalized polarizing pulses to 100 mV (400 ms) at intervals of 15 s for n54 experiments. There was no significant shift in the ( Fig. 6A ) and 1 s (Fig. 6B) Control currents and currents after application of carvedilol were normalized to their peak currents and in additional graphs, the degree of inhibition was shown with logarithmic and linear time scale.
Normalized macroscopic currents over 30 s scaled for washin periods of 2 and 5 min ( Fig. 7A and B) . Although, analysis of the first 600 ms revealed a steady increase of inhibition from almost 0% immediately after the test pulse to about 80% at 600 ms (Fig. 7C ). This can be interpreted as a very fast open channel block within the first 400 ms of the measurements. Other experimental findings support this result as well: The faster development of stable current under carvedilol where control activating current still increased (Fig. 1) and a slight decrease of activating current under 10 mM carvedilol during the first 400 ms of Fig. 2C . In Fig. 7 , the peak current was reached after about application demonstrated, that there was no significant time-dependent run-down (n54, data not shown).
steady-state block after 70 s of repetitive step pulses might be taken as a measure for the frequency dependence of 4. Discussion block. We found, that at both frequencies the current amplitudes did not change. Therefore the block of HERG This study demonstrates that the HERG potassium currents by carvedilol is not frequency and not use-depenchannel is blocked by carvedilol. The HERG potassium dent within this protocol that has a test pulse duration of channel produces the I potassium current in carKr 400 ms according to the QT-interval in the ECG. The lack diomyocytes. Recently it has been shown that carvedilol of use-dependence despite an open channel block by blocks I in isolated rabbit cardiomyocytes. This indicates Kr carvedilol is mainly caused by the fast velocity of block, that the block of this channel occurs also in native cardiac which allows complete inhibition within one single step.
cells [6] . The effects of carvedilol on HERG in our study So the subsequent pulses cannot intensify the block.
and I currents in the study by Cheng et al. parison to the block of I in cardiomyocytes (IC 50.4 treated patients [1] . In the PRECISE trial, a significant Kr 50 mM; [6]) a higher concentration of carvedilol was necesdecrease in the combined risk of morbidity and mortality sary in our study to inhibit HERG channels expressed in could be shown for moderate to severe heart failure [33] . Xenopus oocytes (IC 510.4 mM). This difference is Sudden cardiac death due to malignant arrhythmias and 50 attributed to the viteline membrane and yolk of the pump failure are the most common causes of death in oocytes, which requires up to 10-to 30-fold higher patients with severe heart failure. Although some clinical concentrations for the drug effects [28, 20] . Taking this into trials describe a reduction of ventricular arrhythmias under consideration, this study and the study of Cheng et al. [6] carvedilol treatment [39, 7] , the reduction of sudden death indicate that the block of HERG channels by carvedilol is mortality under carvedilol in the clinical trials have not yet of therapeutical relevance for treated patients.
been explained. It may be possible that the reduction of Clinical trials with carvedilol have proven that this drug malignant arrhythmias and consequently the reduction of is effective in the therapy of ischemic and idiopathic heart sudden cardiac death may be at least, in part, the result of failure. Beneficial effects on mortality and hospitalisation an antiarrhythmic effect of carvedilol by blocking HERG rate have been demonstrated in the trial of the US potassium channels. This potentially antiarrhythmic effect Carvedilol Heart Failure Study Group. Carvedilol reduced together with its b-blocking properties may be responsible the mortality by 65% in patients with either form of for the positive outcome of the clinical trials. cardiomyopathy [33] . In the trial of the Australia-New
We found, that blockade of HERG potassium channels Zealand Heart Failure Research Collaborative Group, by carvedilol appears to occur rather quickly and almost carvedilol increased the left ventricular ejection fraction of exclusively on open states (Fig. 7C) . The lack of usepatients with heart failure due to ischemic heart disease by dependence is a sign of very fast development of complete 5.3% and the rate of death or hospital admission was lower block already during one short test pulse. The onset of in the carvedilol group [12] . The MOCHA multicenter trial block by carvedilol is fast and occurred within 2-3 min. for patients with mild to moderate heart failure demonThis is much faster than block of HERG channels by strated a decrease of mortality risk by 73% in carvediloldofetilide [22] or block of HERG channels by amiodarone protecting against lethal reperfusion injury. Eur J Pharmacol [25] . We speculate, that carvedilol blocks HERG channels 
